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Abstract
Introduction: We sought to determine whether protocol biopsies
could be used to guide treatment and improve outcomes in simultaneous pancreas-kidney (SPK) patients.
Methods: Between 2004 and 2013, protocol biopsies were performed on SPK patients at 3–6 months and one year post-transplant.
Maintenance immunosuppression consisted of a calcineurin inhibitor, anti-proliferative agent, and corticosteroid. Corticosteroid was
withdrawn in negative early biopsies, maintained in subclinical/
borderline biopsies, and increased if Banff IB or greater rejection
was identified. Endpoints included presence of interstitial fibrosis
and tubular atrophy on biopsy at one year (IF/TA), rejection episodes, and renal and pancreas function at five years’ followup.
Results: Forty-one SPK transplant patients were reviewed and a
total of 75 protocol biopsies were identified. On early biopsy,
51% had negative biopsies, 44% had borderline rejection, and 5%
had subclinical rejection. Renal and pancreas function were not
significantly different at one, two, and five years post-transplant
between negative vs. borderline early biopsy patients. No difference in the degree of IF/TA was found between these two groups.
Conclusions: To our knowledge, this is the first study to evaluate
protocol biopsies as an investigative tool prior to steroid withdrawal
in SPK patients. Our study suggests that there are no detrimental functional or histological effects at five years post-transplant,
despite weaning steroids in the negative biopsy group.

Introduction
Interstitial fibrosis and tubular atrophy (IF/TA) is the principle
cause of kidney allograft failure and is commonly precipitated by episodes of acute rejection.1 While recent improvements in immunosuppressive therapy have reduced the inci-
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dence of acute rejection, these pharmacological advances
have not translated into a reduction in the prevalence of IF/
TA or an improvement in long-term outcomes.2,3 Current
literature suggests that clinically undetectable graft pathology (including borderline and subclinical rejection) may
be a predictor of future development of IF/TA and eventual
graft loss.3-5
Subclinical rejection refers to a histological finding of
acute cellular rejection using the Banff criteria (≥grade IA)
in the absence of renal dysfunction.3,6 Borderline rejection is
defined as Banff grade <IA in the absence of renal dysfunction. While some authors consider borderline rejection to
be grouped with subclinical rejection, the significance of
borderline rejection is largely unknown.3
Protocol biopsies are histological allograft samples taken
at predetermined times after transplant, in the absence of
any clinically detectable graft dysfunction. These biopsies
provide the opportunity to recognize silent graft pathology
(subclinical/borderline changes) in a timely manner and
potentially optimize treatment to prolong graft function
and survival. A study by Nankivell et al demonstrated a
high incidence of IF/TA in simultaneous pancreas-kidney
(SPK) patients undergoing protocol biopsies.1 However,
these biopsies were not used to guide subsequent treatment of patients.
Steroid withdrawal has been controversial in SPK patients,
as more antiquated studies suggest that rejection rates and
renal function are potentially impacted if steroids are withdrawn in all patients irrespective of rejection risk.7 In our
cohort of SPK patients, we aimed to wean corticosteroids
in patients with an absence of subclinical or borderline
rejection at three months in order to reduce steroid-related
complications. The overall aim of this study was to determine whether identification of subclinical pathology with
protocol biopsies could be used to select SPK patients for
safe steroid withdrawal.
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Methods

Outcomes

Patients

The outcomes measured included creatinine, estimated
glomerular filtration rate (eGFR), presence of IF/TA, number
of rejection episodes, and HbA1c.

The institutional review board approved our study. The study
group consisted of 61 consecutive SPK transplant recipients. All recipient surgeries occurred at the London Health
Sciences Centre (LHSC) between January 2004 and August
2013. Biopsies were read at LHSC by the pathology department. Patients were followed for a minimum of five years
post-transplant. Protocol biopsies were performed on all SPK
patients at 3–6 months. Exclusion criteria included: 1) patient
declining protocol biopsy (four patients); 2) patient non-compliance (four patients); 3) early graft loss (seven patients); and
4) postoperative anticoagulation therapy (five patients).

Statistics
Statistical analysis was carried out using GraphPad Prism
6.0 software (GraphPad Software, Inc. La Jolla, CA, U.S.).
T-test was used for the comparison of means and standard
deviations of the two groups. Log-rank (Mantel-Cox) test was
used to compare graft and patient survival. Analysis was
intention to treat based on their initial early protocol biopsy.
Differences were considered significant when p<0.05.

Results

Immunotherapy
All SPK patients received anti-thymocyte globulin (total
5–8 mg/kg) for induction immunosuppression and continued on three-drug maintenance immunosuppression
(combination of calcineurin inhibitor [tacrolimus], antiproliferative agent [mycophenolate mofetil or sirolimus],
and corticosteroid). Target tacrolimus levels were 5–8
ng/ml in the first three months and 3–5 ng/ml thereafter.
Methylprednisolone was initiated at 250 mg IV, reduced
to 1 mg/kg IV, and reduced daily by 10 mg until oral
prednisone was administered at 5 mg daily.

Protocol biopsies
The early 3–6-month protocol biopsy determined the decision to alter corticosteroid therapy. Biopsies were performed
under ultrasound guidance with a Monopty biopsy gun
(Bard®, Covington GA, U.S.). The biopsy was adequate if
a minimum of two full cores with a total of >8 glomeruli
were available for assessment under microscopy. If there
was no sign of rejection on the biopsy, the prednisone dose
was tapered and withdrawn over two weeks. If there was
borderline rejection on the biopsy, then prednisone therapy
was maintained at 5 mg daily. If Banff IB or greater rejection was identified, patients were treated with methylprednisolone boluses (250 mg then 1 mg/kg the next day, with
reductions of 10 mg daily until a dose of 5 mg daily was
achieved). Repeat biopsy within nine months was performed
to determine presence or absence of rejection or IF/TA.
Protocol biopsies were not performed on the pancreas
graft due to technical difficulties in visualizing the pancreas
and risk of pancreatitis or bleeding. As well, assessment of
post-transplant donor-specific antibodies was not performed
in our patients and is currently not part of our post-transplant
monitoring protocol.

Patients and graft survival
Forty-one consecutive SPK transplant patients were reviewed.
Donor and recipient characteristics were similar between the
steroid withdrawal group (no rejection on protocol biopsy)
and the group maintained on steroids (borderline or acute
rejection). Demographics are displayed in Tables 1 and 2.
The five-year death-censored renal graft survival rate was
95% in the steroid withdrawal and 100% in the maintenance
group (p=NS). The graft losses were secondary to infections
and non-compliance. The five-year death-censored pancreas
graft survival rates were identical at 85% in each group.
Graft losses were secondary to non-compliance and infections, as well as to the development of post-transplant diabetes mellitus from obesity.

Rejection
A total of 41 early protocol biopsies were performed in 41
patients between three and six months. Twenty-six out of 41
patients had one-year followup protocol biopsies that were
adequate for analysis; 12 of 41 patients had 16 additional
protocol biopsies beyond the followup biopsy. Overall, a
total of 85 protocol biopsies were performed. In addition
to protocol biopsies, 24 of 41 patients underwent for-cause
biopsies for allograft dysfunction at some point during the
five years of followup.
Fifty-one percent of patients had no histological changes on early protocol biopsy (negative biopsy group) and
prednisone therapy was withdrawn. The one-year protocol
biopsy of these patients (n=14) showed that 57% remained
negative, 36% developed borderline rejection, and 7%
developed Banff IB rejection. Patients who later developed
borderline rejection were restarted on steroid therapy. Forty-
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Table 1. Donor demographics

Table 2. Recipient demographics

Characteristic

Age
Kidney CIT
Pancreas CIT
BMI (kg/m2)

Characteristic
Negative biopsy
(steroid withdrawal)
31.8±12.3
5.78±2.47
6.47±2.60

Positive biopsy
(steroid maintained)
29.4±10.7
6.96±2.58
8.13±3.06

p
NS
NS
NS

25.85±2.99

25.6±4.2

NS

Data are mean ± standard deviation. BMI: body mass index; CIT: cold ischemic time.

four percent of patients had borderline changes on early
protocol biopsy (borderline biopsy group) and prednisone
therapy was maintained. The one-year protocol biopsy of
these patients (n=11) showed that 36% were negative, 55%
remained borderline, and 9% developed C4d+/DSA+ subclinical humoral changes (Fig. 1).
Of note, IFTA was quantified using the Banff classification. Grade I represented mild IF/TA and Grade II represented moderate IF/TA. There was only one case of Grade
II IF/TA on protocol biopsy. The remaining protocol biopsies
were Grade I IF/TA.
There was no difference in the percentage of IF/TA
between the negative vs. borderline biopsy groups at one
year (56% vs. 50%; p=0.81) or at any protocol biopsy time
point (67% vs. 67%; p=1). There was also no difference in
the number of clinical rejection episodes in the five years of
followup between the two groups (17% vs. 25%; p=0.62).
Total early protocol
biopsies (n=26)

Negative (n=12)
46%
Steroid withdrawn

Borderline (n=12)
46%
Steroid maintained

Subclinical (n=2)
8%
Steroid bolus

1-year protocol
biopsy (n=9)

1-year protocol
biopsy (n=10)

1-year protocol
biopsy

Negative (n=5)
56%

Negative (n=4)
40%

Borderline (n=3)
33%

Borderline (n=5)
50%

Banff 1B (n=1)
11%

C4d+/DSA+
(n=1)
10%

Borderline
(n=1)a

Fig. 1. Early protocol biopsy results. Twenty patients had one-year followup
protocol biopsies that were adequate for analysis. aPatients later developed
antibody-mediated rejection at 18 months.
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Age
Sex (male %)
Race (caucasian %)
Transplant number
(first %)
PRA %
Dialysis (% HD)

Negative biopsy
(steroid
withdrawal)
43.8±8.70
55%
95%
100%

Positive biopsy
(steroid
maintained)
41.9±9.13
65%
100%
100%

0.7±2.8
60%

1.2±3.4
71%

p

NS
NS

NS
NS

Data are mean ± standard deviation. HD: preoperative mode of dialysis = hemodialysis;
PRA%: % panel reactive antibody.

Two early protocol biopsies (5%) demonstrated subclinical rejection (Banff IA). The first patient received prednisone
maintenance successfully, but refused any further protocol
biopsy and had excellent renal and pancreatic graft function
at five years. The second patient had a biopsy demonstrating
Banff IA rejection. He was successfully treated with prednisone bolus therapy. He later developed Banff IIA rejection
with C4d+/DSA+ antibody-mediated rejection at 18 months,
demonstrated on followup protocol biopsy, despite having
excellent graft function (creatinine 105 µmol/L, HbA1c
0.056). He was treated with plasmapheresis/intravenous
immunoglobulin 2 g/kg and prednisone therapy, but lost
his renal allograft from ongoing rejection four years posttransplant. He remains insulin-independent. One patient in
the borderline group had a rising amylase despite having a
stable serum creatinine at nine months postoperatively. This
patient had a negative renal biopsy, but since the amylase
remained elevated, the pancreas was biopsied one week
later; this showed no evidence of rejection.
Four patients were excluded from the study because they
declined the early protocol biopsy. Three of these patients
received a biopsy at one year, which showed borderline
changes. One of these patients subsequently developed antibody-mediated rejection at six months. The fourth patient
never received any protocol biopsies. He later developed
IF/TA, demonstrated on a for-cause biopsy at 11 months.

Graft function and survival
The three-month (89 vs. 105 µmol/L; p=0.05) and two-year
(90 vs. 105 µmol/L; p=0.04) post-transplant serum creatinine
was statistically lower in the negative vs. borderline biopsy group (Table 3). However, the five-year post-transplant
serum creatinine was not significantly different between
the two groups. More importantly, there was no difference
in the eGFR, as calculated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation between
the two groups at three months (90 vs. 80 ml/min/1.72 m2;
p = 0.21), one year (75 vs. 76 ml/min/1.72 m2; p=0.85), two
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Table 3. Renal function and survival for negative and
borderline early protocol biopsies

Mean Cr

3 months
1 year
2 years
5 years
Mean eGFR
3 months
1 year
2 years
5 years
5-years graft survival

Negative
(steroid
withdrawal)
89±16
97±17
90±14
92±14
90±21
75±16
82±22
65±9
95%

Positive
(steroid
maintained)
105±30
107±20
105±29
113±15
80±20
76±15
75±18
55±18
100%

Table 4. Pancreas function and survival for negative and
borderline early protocol biopsies
p

0.05
0.04
0.04
0.01
NS
NS
NS
NS
NS

Data are means ± standard deviation. CR: creatinine; eGRR: estimated glomerular filtration
rate; NS: non-significant.

years (82 vs. 75 ml/min/1.72 m2; p=0.53), andfive years (65
vs. 55 ml/min/1.72 m2; p=0.91) post-transplant. The fiveyear kidney graft survival was 95% and 100% in the negative
and borderline biopsy groups, respectively (p=NS).
In terms of pancreatic transplant function, both groups
displayed similar HbA1c levels at three month (0.053 vs.
0.056; p=NS), one year (0.053 vs. 0.058; p=0.05), and five
years (0.053 vs. 0.048; p=NS) post-transplant. The percentage of patients who remained insulin-free was the same in
both groups at five years (Table 4).

Steroid-related complications
We did not detect a difference in common steroid-related
complications, including impaired glucose tolerance, hypertension, and dyslipidemia, between the negative and borderline biopsy groups (Table 5). As well, none of the patients
developed avascular necrosis of the hips and four patients
in each group had cataract surgeries in the five years following transplantation.

Discussion
In this study, 44% of patients had early protocol biopsies
demonstrating borderline rejection and 5% had subclinical
rejection. These results are consistent with the findings of
Nankivell et al, who demonstrated subclinical rejection
(acute and borderline) in 45.7% of patients at three months.1
In addition, our protocol biopsies demonstrated a high percentage of IF/TA at one year. The ability to detect subclinical
rejection and IF/TA in kidney-only transplant patients had
previously been shown to allow early treatment that may
theoretically prolong graft function and survival.6,8 Choi et
al demonstrated that subclinical rejection detected at two
weeks post-transplant was associated with a 30% decrease
in graft survival at 10 years compared to those with normal
findings.8 A small, randomized control trial by Rush et al

Mean HbA1c

3 months
1 year
5 years
5-year graft survival

Negative
(steroid
withdrawal)
0.053±0.009
0.052±0.005
0.053±0.006
85%

Borderline
(steroid
maintained)
0.056±0.008
0.058±0.009
0.048±0.004
85%

p

NS
0.05
NS
NS

Data are means ± standard deviation. Pancreas graft survival is indicated by recipients
being insulin-free. HbA1c: hemoglobin A1c; NS: non-significant.

showed that treatment of subclinical rejection detected by
protocol biopsies lead to better histological and functional
outcomes in renal transplant patients compared to patients
with no protocol biopsies.6 Recent findings from Loupy et al
showed that there are two distinct phenotypes of subclinical
rejection, T cell-mediated rejection (TCMR) and antibodymediated rejection (ABMR), which are associated with distinct outcomes.9 Specifically, subclinical ABMR detected on
one-year protocol biopsy was associated with the poorest
graft survival compared to the subclinical TCMR or negative
biopsy groups.9 The distinction of subclinical TCMR and
ABMR was not within the scope of our study.
The use of corticosteroids is an integral part of immunosuppressive therapy, but is also associated with multiple
adverse effects, including bone demineralization, weight
gain, impaired glucose tolerance, and heart disease. 10
Therefore, steroid withdrawal is a worthwhile goal in the
management of SPK patients post-transplant. However, historical publications have indicated that steroid withdrawal
may increase rejection and inferior long-term survival in
renal transplant recipients.7 In our study, the early protocol biopsy was used to determine whether steroid therapy
could be withdrawn in those patients at low risk for subsequent acute/chronic rejection. We assumed that patients
with a negative early protocol biopsy represented a “lowrisk” population. In these patients, steroid withdrawal did
Table 5. Steroid-related complications for negative and
borderline early protocol biopsies

Negative
(steroid withdrawal)
Positive
(steroid maintained)

Negative
(steroid withdrawal)
Borderline
(steroid maintained)

LDL pre-transplant
LDL 1 year
(mmol/L)
post-transplant
1.9±0.5
2.1±0.6

p
NS

1.7±0.6

2.0±0.6

NS

Blood pressure
pre-transplant
(mmHg)
137/77

Blood pressure
post-transplant
(mmHg)
131/72

NS

128/69

130/76

NS

LDL: low- density lipoprotein; NS: non-significant.
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not lead to increased histopathological changes at one year
compared to borderline/subclinical biopsy patients who
were maintained on steroids. There was also no difference
in the eGFR or HbA1c between the two groups at five years
post-transplant. This suggests that there are no functional
detrimental effects despite weaning steroids in the negative early biopsy group. Therefore, the early protocol biopsy
identified a group in whom steroid therapy could be successfully weaned. Compared with early steroid withdrawal
(within one week) in all patients, minimal steroid exposure
is not achieved using our approach, which may have limited
our ability to reduce all steroid-related complications. Our
biopsy approach, therefore, offers a compromise between
early withdrawal and steroid maintenance strategies.
Unlike subclinical rejection, in which treatment is generally supported, the clinical benefit of treating borderline rejection is less clear. Roberts et al reported that early biopsy showing borderline changes go on to develop clinical rejection
if left untreated.11 Nankivell et al showed that patients with
borderline rejection had subsequent biopsies showing higher
grades of chronic rejection.1 Herein, we did not detect a difference between the negative vs. borderline biopsy groups in
the number of patients with IF/TA at one year and the number
of clinical rejection episodes at five years post-transplant. This
finding suggests that low-dose prednisone may be beneficial
in preventing worsening of IF/TA in the borderline rejection
group. Greater numbers are needed to determine whether
modification of immunotherapy (steroid boluses, increasing
immunotherapy dose) of this “at-risk” group will reduce IF/
TA and improve long-term graft survival.
In our protocol biopsies, only the kidney transplant is
biopsied. Our steroid withdrawal protocol assumes that
concordant rejections occur within both kidney and pancreatic allografts. However, it is believed that there may
be a significant discordance between renal biopsies and
pancreatic allograft biopsies with regards to the detection
of rejection.12 As the clinical impact of protocol biopsies of
the pancreas transplant has not been studied, it is unknown
whether discordance in subclinical rejections can also occur
in pancreas and kidney allografts.
There are a few limitations to this study. First, this was a
retrospective chart review and patients were not randomized to steroid withdrawal vs. maintaining steroid therapy in
either group. Therefore, the true significance of steroid withdrawal on renal function and histology of biopsy-negative
patients is unknown, and potentially, the rates of IF/TA could
have been reduced if corticosteroids were not withdrawn
on the biopsy-negative group. Importantly, the number of
patients included in this study was small, and the impact of
steroid withdrawal on steroid-related factors was beyond the
scope of the study. These weaknesses were balanced by the
long followup of a minimum of five years in our cohorts. We
recommend a study using greater patient numbers in order
192

to determine the optimal approach in treating borderline
rejection discovered on protocol biopsy in SPK patients.

Conclusion
To our knowledge, this is the first study to evaluate the role
of protocol biopsies in guiding steroid withdrawal for SPK
transplant patients. Our study suggests weaning steroids in the
negative early biopsy group does not lead to worse functional
or histological pathology at five years post-transplant vs. the
borderline group. Further investigations are needed to determine the significance of borderline rejection and whether
immunotherapeutic modifications have any impact on IF/TA.
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